By examining data from these trials, we conclude that (1) during treatment of cancer patients with PD-L1 mutations/positive, current smokers are more likely to respond better than the non-smokers when treated with one of four of the five anti-PD-1 and PD-L1 drugs: Nivolumab, Pembrolizumab, Atezolizumab, and Avelumab. This evidence concerns the gene CD274 and cancer.